HDV

Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline

Retrieved on: 
목요일, 5월 9, 2024
T. Rowe Price, HBM, HDV, New Board, Therapy, EMA, General partnership, Wellington Management Company, Series, SAN, Global health

SAN MATEO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a leader in the development of novel therapeutics, today announced the successful closure of a $182 million Series C financing round.

Key Points: 
  • SAN MATEO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a leader in the development of novel therapeutics, today announced the successful closure of a $182 million Series C financing round.
  • This capital infusion will accelerate the clinical development of BJT-778, as the treatment for chronic hepatitis D (HDV).
  • The funds will also support the progression of additional promising candidates in Bluejay's robust pipeline for the treatment for chronic hepatitis B.
  • Following the completion of the Series C financing, Bluejay is excited to welcome New Board Member, Daniel Estes, a General Partner at Frazier, to its Board of Directors.

Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

Retrieved on: 
수요일, 5월 8, 2024
Assembly, EASL, HDV, Gilead Sciences, Safety, Viral, Simplex, Research, HSV, Therapy, Clinical trial, Biotechnology, HBV

“These clearances are a significant step toward our goal of reaching key clinical inflection points for multiple programs in our antiviral pipeline by year end.

Key Points: 
  • “These clearances are a significant step toward our goal of reaching key clinical inflection points for multiple programs in our antiviral pipeline by year end.
  • Assembly Bio’s cash position is projected to fund operations into the second half of 2025.
  • Revenues from collaborative research were $5.8 million for the three months ended March 31, 2024.
  • Revenue for the three months ended March 31, 2024 consists of amounts recognized under the collaboration with Gilead.

Current Affairs: The Trends Shaping EV Charging Technology, Reports IDTechEx

Retrieved on: 
목요일, 4월 18, 2024
Hydrogen, MCS, HDV, Toyota, Volvo, BEV, Traction, Electricity, Research, Watt, CCS, CONFIG.SYS, EV, Fleet, Hitachi, GM, Electric vehicle, AC, Daimler, Government, Growth, Players

BOSTON, April 18, 2024 /PRNewswire/ -- Based on their ongoing research into the EV charging market, IDTechEx estimates that 222 million chargers will be needed by 2034 to support the growing global EV fleet. IDTechEx also predicts that the cumulative global investment in global charging infrastructure will exceed $123 billion by 2034 (hardware cost alone). IDTechEx research aims to keep up with the changes and developments in EV charging by monitoring and analyzing the EV charging industry, its developments and regulations, and the latest technological trends and innovations.

Key Points: 
  • IDTechEx's report " Charging Infrastructure for Electric Vehicles and Fleets 2024-2034 " covers the trends and developments in the EV charging industry.
  • The IDTechEx charging infrastructure market report provides an in-depth coverage of multiple types of EV charging solutions including private AC charging, public DC charging, megawatt charging, battery swapping, and wireless charging.
  • Technologies like destination or wallbox DC chargers, megawatt charging, robotic charging, battery-buffered charging, off-grid charging, and mobile charging are some examples of the emerging EV charging solutions included in the research from IDTechEx.
  • IDTechEx has the most comprehensive EV charging research portfolio spanning major technologies like traditional conductive charging , wireless charging , battery swapping , and off-grid charging encompassing all vehicle segments already being electrified.

Current Affairs: The Trends Shaping EV Charging Technology, Reports IDTechEx

Retrieved on: 
목요일, 4월 18, 2024
Hydrogen, MCS, HDV, Toyota, Volvo, BEV, Traction, Electricity, Research, Watt, CCS, CONFIG.SYS, EV, Fleet, Hitachi, GM, Electric vehicle, AC, Daimler, Government, Growth, Players

BOSTON, April 18, 2024 /PRNewswire/ -- Based on their ongoing research into the EV charging market, IDTechEx estimates that 222 million chargers will be needed by 2034 to support the growing global EV fleet. IDTechEx also predicts that the cumulative global investment in global charging infrastructure will exceed $123 billion by 2034 (hardware cost alone). IDTechEx research aims to keep up with the changes and developments in EV charging by monitoring and analyzing the EV charging industry, its developments and regulations, and the latest technological trends and innovations.

Key Points: 
  • IDTechEx's report " Charging Infrastructure for Electric Vehicles and Fleets 2024-2034 " covers the trends and developments in the EV charging industry.
  • The IDTechEx charging infrastructure market report provides an in-depth coverage of multiple types of EV charging solutions including private AC charging, public DC charging, megawatt charging, battery swapping, and wireless charging.
  • Technologies like destination or wallbox DC chargers, megawatt charging, robotic charging, battery-buffered charging, off-grid charging, and mobile charging are some examples of the emerging EV charging solutions included in the research from IDTechEx.
  • IDTechEx has the most comprehensive EV charging research portfolio spanning major technologies like traditional conductive charging , wireless charging , battery swapping , and off-grid charging encompassing all vehicle segments already being electrified.

Bluejay Announces Receipt of PRIME Designation from European Medicines Agency (EMA) for BJT-778 for the Treatment of Chronic Hepatitis Delta Virus Infection

Retrieved on: 
월요일, 3월 25, 2024
Therapy, Patient, SAN, HDV, European Medicines Agency, PRIME, Hepatology, Immunoglobulin G, Blue jay, Disease, EMA

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc., a private clinical-stage biopharmaceutical company focused on viral and liver diseases, today announced the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to BJT-778 for the treatment of Chronic Hepatitis Delta Virus (HDV) infection.

Key Points: 
  • SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, Inc., a private clinical-stage biopharmaceutical company focused on viral and liver diseases, today announced the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to BJT-778 for the treatment of Chronic Hepatitis Delta Virus (HDV) infection.
  • BJT-778 is a high-potency, fully human immunoglobulin G1 (IgG1) mAb that acts as an anti-viral to HDV by neutralizing and facilitating the clearance of HDV virions.
  • The application for PRIME designation was bolstered by compelling data from non-clinical studies, along with interim results from the company's Phase 1/2 study that included subjects with chronic HDV.
  • “We eagerly anticipate our continued collaboration with the EMA and other regulatory agencies to expedite the availability of this promising treatment for patients.”

Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule

Retrieved on: 
화요일, 3월 5, 2024
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Alanine transaminase, HDV, ALT, Clinical research, Cirrhosis, Safety, RNA, CHD, Patient, Clinical trial, Hepatitis, Pharmaceutical industry

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed enrollment of its current cohorts one month earlier than anticipated.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed enrollment of its current cohorts one month earlier than anticipated.
  • Initial data are expected in the second quarter of 2024.
  • SOLSTICE is a Phase 2 multi-center, open-label trial designed to evaluate the safety, tolerability, and efficacy of tobevibart and elebsiran in adult participants (age 18 to 69) with CHD infection receiving nucleot(s)ide reverse transcriptase inhibitor therapy.
  • Depending on the cohort, trial participants are receiving multiple doses of tobevibart and elebsiran as either monotherapy or in combination administered via subcutaneous injection for up to 88 weeks.

Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024

Retrieved on: 
월요일, 2월 26, 2024
Biotechnology, FDA, AIDS, Health, Pharmaceutical, Research, Infectious Diseases, Hospitals, Science, COVID-19, Clinical Trials, Senior, Hepatitis B, CROI, Hook effect, RWE, STR, Viral, Virus, DTG, Mortality, Lenacapavir, Hepatitis, HBV, Vesatolimod, Fungal infection, HIV-1, MDR, PWH, HDV, Boxed warning, European, Islatravir, Tablet, European Commission, Liver disease, Omicron, Conference, Safety, ART, Civil service commission, Abstract, Bictegravir, Natural history, Virology, Emtricitabine, Gilead Sciences, MD, Food, Coinfection, Immunodeficiency, European Economic Area, Risk, Prevalence, Dexamethasone, Patient, Tuberculosis, INSIGHT, HIV, Pharmaceutical industry

Outcomes from pipeline research studies will also provide insights into investigational treatment candidates, including the novel combination regimen of lenacapavir plus bictegravir.

Key Points: 
  • Outcomes from pipeline research studies will also provide insights into investigational treatment candidates, including the novel combination regimen of lenacapavir plus bictegravir.
  • Additionally, a late-breaker oral presentation of Week 24 data from the INSIGHT trial evaluating Biktarvy in people with HIV and tuberculosis will be presented.
  • Gilead will present new data evaluating the safety and efficacy of Hepcludex® (bulevirtide) in people living with the coinfections of HIV, hepatitis B (HBV) and hepatitis delta (HDV).
  • Biktarvy combines the novel, unboosted INSTI bictegravir, with the Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, F/TAF) backbone.

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
목요일, 2월 22, 2024
Biotechnology, Pharmaceutical, AIDS, Health, COVID-19, Infectious Diseases, Health Technology, Clinical Trials, Infection, Bangladesh Technical Education Board, RSV, CHB, Influenza, Peginterferon-alfa, HIV Vaccine Trials Network, GSK, Research, Investment, AASLD, HDV, MBA, Cirrhosis, HHS, Administration, Conditional sentence, Hepatology, RNA, Respiratory syncytial virus, ASPR, COVID, Patient, Family, HCMV, Bill, Development, HIV, Pharmaceutical industry

Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
  • Complete 24-week treatment data for 30 participants per regimen is expected in the fourth quarter of 2024.
  • The MARCH Part B trial is ongoing with 48-week end of treatment data expected in the fourth quarter of 2024.
  • Revenues: Total revenues for the quarter ended December 31, 2023 were $16.8 million compared to $49.4 million for the same period in 2022.

Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
화요일, 2월 6, 2024
Oncology, Health, Infectious Diseases, Hospitals, COVID-19, Pharmaceutical, Biotechnology, EPS, IPR, Compugen, Immunotherapy, Food and Drug Administration, ETR, Dow Jones Sustainability Indices, Progression-free survival, Obeldesivir, FDA, Virology, FTC, Hematology, ALL, HDV, Society, Neurotoxicity, Acquisition, HCV, Cell therapy, Acute lymphoblastic leukemia, MYR, Research, HIV, Patient, Tenofovir alafenamide, Food, Infection, Multiple myeloma, Standard of care, OS, Lymphoma, B-cell lymphoma, Table, GAAP, Docetaxel, Lung cancer, Science, Earnings per share, Investment, Liver disease, Risk, ASH, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023.
  • During the fourth quarter 2023, Gilead paid cash dividends of $943 million and utilized $150 million to repurchase common stock.
  • The Liver Disease portfolio sales were $691 million in the fourth quarter 2023 and remained flat compared to the same period in 2022.
  • Cell Therapy product sales increased 11% to $466 million in the fourth quarter 2023 compared to the same period in 2022.

Assembly Biosciences Provides Anticipated Development Milestones for 2024

Retrieved on: 
목요일, 1월 4, 2024
Assembly, Partnership, Outline, Biotechnology, HDV, HBV, Trial of the century, Hepatitis B, Viral, HSV, Patient, Gilead Sciences, Vaccine

Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio across herpesviruses and hepatitis B and D viruses

Key Points: 
  • Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio across herpesviruses and hepatitis B and D viruses
    Recently announced long-term partnership with Gilead Sciences, Inc. (Gilead) to address serious viral diseases expands and builds on the progress of Assembly Bio’s antiviral portfolio
    SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today provided an outline of the anticipated milestones and progress for its clinical pipeline during 2024.
  • “We are thrilled with the rapid progress of multiple programs from our expanded antiviral pipeline, and plan to initiate clinical studies for four development candidates in 2024,” said Jason Okazaki, chief executive officer and president of Assembly Bio.
  • By the end of 2024:
    Two additional candidates are anticipated to enter the clinic:
    ABI-1179, the long-acting HSV helicase-primase inhibitor contributed by Gilead under the collaboration between Assembly Bio and Gilead; and
    ABI-6250, a small molecule orally-bioavailable hepatitis delta virus entry inhibitor.
  • Initial clinical data are expected to be available from both the ABI-5366 first-in-human clinical study and the ABI-4334 Phase 1b study.